Source: Lancet oncology. Unidade: FM
Subjects: LINFOMA, IMUNOTERAPIA, ESTUDOS RANDOMIZADOS, ANTINEOPLÁSICOS
ABNT
ROBAK, Tadeusz et al. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study. Lancet oncology, v. 19, n. 11, p. 1449-1458, 2018Tradução . . Disponível em: https://doi.org/10.1016/S1470-2045(18)30685-5. Acesso em: 28 set. 2024.APA
Robak, T., Jin, J., Pylypenko, H., Verhoef, G., Siritanaratkul, N., Drach, J., et al. (2018). Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study. Lancet oncology, 19( 11), 1449-1458. doi:10.1016/S1470-2045(18)30685-5NLM
Robak T, Jin J, Pylypenko H, Verhoef G, Siritanaratkul N, Drach J, Raderer M, Mayer J, Pereira J, Tumyan G. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study [Internet]. Lancet oncology. 2018 ; 19( 11): 1449-1458.[citado 2024 set. 28 ] Available from: https://doi.org/10.1016/S1470-2045(18)30685-5Vancouver
Robak T, Jin J, Pylypenko H, Verhoef G, Siritanaratkul N, Drach J, Raderer M, Mayer J, Pereira J, Tumyan G. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study [Internet]. Lancet oncology. 2018 ; 19( 11): 1449-1458.[citado 2024 set. 28 ] Available from: https://doi.org/10.1016/S1470-2045(18)30685-5